Originally published in the Record
KITCHENER — In the lab at Rapid Novor, a molecular scientist lays bare the microscopic-building blocks of antibodies that are increasingly used in the fight against cancer, diagnostics and new medicines.
Rapid Novor, a startup that went through the Accelerator Centre in the David Johnston Research and Technology Park, is now based at 44 Gaukel St. in downtown Kitchener. Specializing in what’s called protein sequencing, the six-member team is among a small, but growing, number of biotech startups in the region.
The human body produces antibodies to fight diseases and infections. Antibodies are made of protein. And protein is made of amino-acids — the building blocks of human life.
There about 20 common types of amino acids. Rapid Novor has combined its software with the latest in laboratory equipment and, after investing a million dollars to open the lab, it can quickly determine which amino acids make up an antibody. Just as importantly, it discovers the order, or sequence, of those amino acids, which are long, chain-shaped molecules.
That information is used to make drugs, diagnose diseases and treat cancer, said Zac McDonald, a molecular scientist and biochemist at Rapid Novor.
“That’s why the interest in it is so high because there is a lot of potential for using antibodies in cancer treatment,” said McDonald.
The antibodies can direct drugs to the right targets or block certain pathways associated with cancer.
“It is a huge, multibillion market,” said McDonald, who emigrated from South Africa in April to join the startup in downtown Kitchener.
The lab where McDonald works is the first of its kind in this region, and among the few anywhere that has the equipment for what is called next-generation-protein sequencing.
Traditionally, that would take up to two months to do Rapid Novor can do in one week. It is because of the latest equipment in mass spectrometry lab coupled with the algorithm developed by one of the startup’s co-founders — Dr. Bah Ma, the president and chief scientist at Rapid Novor. Ma is also a professor at the University of Waterloo.
Gene sequencing is not new. Using a sample of saliva, there are companies that sequence the genes in your DNA to see what diseases or conditions you are likely to develop during your lifetime, or where your ancestors are from. That’s called genomics.
Protein molecules are made up of long chains of amino acids. Identifying the different parts of that chain, and the correct order of those parts, is called proteomics. Rapid Novor has the first proteomics-grade lab in this region.
It April 2015 Ma, a professor at the Cheriton School of Computer Science at the University of Waterloo, was ready to commercialize his algorithms that automated a key part of this scientific field. The sophisticated machines analyze the protein samples, identifying the amino acids and producing huge amounts of information.
In the past it would take a scientist up to two months to sort all of that information. Ma’s algorithm does that automatically and quickly. Rapid Novor can have results for clients, which include big and small pharmaceutical companies, in three weeks. For a special fee it can be done in as little as one week.
In the past year, it has completed the protein sequence for 120 antibodies.
Mingjie Xie, a co-founder and chief executive officer, said there are tens of thousands, even hundreds of thousands of pieces that make up a protein sequence. The antibody samples that arrive in the lab are in a solution and, at 200 micrograms, are invisible.
After adding enzymes, shaking, spinning and heating a sample, the antibody is broken into its different parts, and ready for analysis in a mass spectrometer machine. That information, coupled with the startup’s algorithms, puts this small lab at the cutting edge.
“This technology is fairly new,” said Xie. “To be able to use it in commercial settings, this is very new service.”
Where did the idea for Brisk Synergies come from?
